Reimbursement & Coding of CytoSorb Therapy
You can find out here in which countries CytoSorb therapy can be specifically coded and billed. For information on countries not listed here, please contact us.
Coding of COVID-19 patients
WHO has assigned a temporary diagnoses code for COVID-19 patients: ICD U07.1.
• U07.1 COVID-19, virus identified by laboratory test and
• U07.2 COVID-19, virus not identified
The CytoSorb therapy is coded with the procedure code 8-821.2 “Extracorporeal adsorption of low and medium sized molecular, hydrophobic substances (including cytokine adsorption)”.
Reimbursement of CytoSorb
According to Appendix 6 of the current German DRG catalogue, the OPS code 8-821.2 is assigned the individually, annually negotiable additional reimbursement ZE2021-09.
Please note that the additional reimbursement ZE2021-09 is split into two treatment procedures that are assigned to it; on the one hand, classic hemoperfusion (e.g., with activated charcoal filters), documented by OPS code 8-856. On the other hand, the CytoSorb therapy to be coded by OPS code 8-821.2. For easier budget negotiations, differentiation and documentation of the different reimbursement rates, the reimbursement code could be extended by a letter, for example:
ZE code OPS code
ZE2021-09-a 8-821.2 Extracorporeal adsorption of low and medium sized molecular, hydrophobic substances
ZE2021-09-b 8-856 Hemoperfusion
The CytoSorb therapy is to be coded, since 1 January 2020, via CHOP-code 99.76.31 „Extracorporeal adsorption of hydrophobic, low- and medium-sized molecular substances. Adsorption of interleukins. Adsorption of cytokines“.
All CytoSorb treatments are to be coded via CHOP 99.76.31 regardless of the indication or target substance for removal. Prior to 2020 there were different CHOP codes depending on the target substance of removal (please see “Switzerland 2019” above for further information).